Fig. 4.
Fig. 4. Long-term follow-up of clonotypic CDRIII-DNA in serum or plasma. Data from patients with NHL (n = 5) and ALL (n = 5) who did or did not relapse (5 patients each in the upper and lower panel). The patients shown in Fig 3 are included with longer follow-up. Clinically active disease and partial remission are depicted as solid bars and complete clinical remission is indicated by open bars. Molecular follow-up is shown above the clinical data: Serum or plasma was either positive (▾) or negative (○) for clonotypic CDRIII-DNA by PCR. ib, immunoblastic lymphoma; cb, centroblasic lymphoma; mc, mantle cell lymphoma; cALL, common ALL; B-ALL, surface immunoglobulin-positive B-cell ALL; lb, lymphoblastic lymphoma.

Long-term follow-up of clonotypic CDRIII-DNA in serum or plasma. Data from patients with NHL (n = 5) and ALL (n = 5) who did or did not relapse (5 patients each in the upper and lower panel). The patients shown in Fig 3 are included with longer follow-up. Clinically active disease and partial remission are depicted as solid bars and complete clinical remission is indicated by open bars. Molecular follow-up is shown above the clinical data: Serum or plasma was either positive (▾) or negative (○) for clonotypic CDRIII-DNA by PCR. ib, immunoblastic lymphoma; cb, centroblasic lymphoma; mc, mantle cell lymphoma; cALL, common ALL; B-ALL, surface immunoglobulin-positive B-cell ALL; lb, lymphoblastic lymphoma.

Close Modal

or Create an Account

Close Modal
Close Modal